3 FTSE 100 dividends I’d buy during the 2020 stock market crash

Some of the biggest FTSE 100 dividends are being cut during the Covid-19 crisis. Here’s my approach to protecting long-term investing income.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’m very much a dividend investor these days, but I frequently caution that the presence of a big yield isn’t always sufficient to make a stock desirable.

That’s been hammered home recently as a string of companies have suspended their dividends in the wake of the coronavirus crisis. Although it’s affecting some that I hold myself, I think it’s a wise move to focus on balance sheet strength right now. But if you want the safest income you can find, what dividends should you go for?

FTSE 100 dividends

Just as we’re only allowed to shop for essentials, investing in companies that provide essentials can help secure more reliable dividends. Prime examples include utilities like Severn Trent (LSE: SVT).

Severn Trent’s share price has been reasonably resilient, losing 17% or so since the virus dip started. That’s not great, but it’s a lot better than the FTSE 100’s 26% fall – and the falls of 50% and more that riskier stocks have experienced.

Severn Trent’s dividend yield has never been one of the market’s biggest. But the share price fall has pushed the forecast yield up to 4.5% now. It’s certainly not guaranteed, and the firm’s income is not immune from the pandemic threat. But it’s surely a lot more reliable than income from companies offering more discretionary products and services.

Network services

National Grid (LSE:NG) is perhaps of even more central importance. And it’s also offers one of my favourite long-term income streams. With a fall of 14% in its share price, the market seems to see it as more resilient too. And, interestingly, National Grid shares are actually up over the past 12 months, by 4%, while the FTSE 100 has lost about a quarter of its value.

Again, the recent fall has made the dividend yield look a bit more attractive. National Grid has traditionally provided yields a little ahead of the general utility sector level, and right now we’re looking at forecasts for around 5.4%.

With operations in North America too, National Grid also offers a bit of international diversity. And that can’t be a bad thing in these restricted times.

Looking at Severn Trent and National Grid together, I’m reminded that more reliable dividends like these are not just for crisis times. No, they can always make a solid core for an income portfolio.

Long term

I also like the approach of seeking companies whose business models are necessarily directed to the long term. That includes AstraZeneca (LSE: AZN), with its multi-year drug development focus. GlaxoSmithKline fits the bill as well, but I’ll just look at one of the two today.

The AstraZeneca share price is yet another that appears resistant to the great sell-off, falling a very modest 11.5%. It’s also another that has actually gained over the past year, up 5%. As such, the recent dip hasn’t done a great deal to the forecast dividend yield, though it still stands at a respectable 3.5%.

AstraZeneca’s operations could well be hurt by the social distancing aspect of the current lockdown, and it might lose work in non-essential areas of the business. But I really don’t see a great threat to the dividend. The firm’s dividend is already keyed to its years-long earnings and balance-sheet expectations. And, in my view, it’s another example of the kind of long-term dividend we should be seeking.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Will the S&P 500 crash in 2026?

The S&P 500 delivered impressive gains in 2025, but valuations are now running high. Are US stocks stretched to breaking…

Read more »

Teenage boy is walking back from the shop with his grandparent. He is carrying the shopping bag and they are linking arms.
Investing Articles

How much do you need in a SIPP to generate a brilliant second income of £2,000 a month?

Harvey Jones crunches the numbers to show how investors can generate a high and rising passive income from a portfolio…

Read more »

Investing Articles

Will Lloyds shares rise 76% again in 2026?

What needs to go right for Lloyds shares to post another 76% rise? Our Foolish author dives into what might…

Read more »

Investing Articles

How much passive income will I get from investing £10,000 in an ISA for 10 years?

Harvey Jones shows how he plans to boost the amount of passive income he gets when he retires, from FTSE…

Read more »

Investing Articles

Down 34% in 2025 — but could this be one of the UK’s top growth stocks for 2026?

With clarity over research funding on the horizon, could Judges Scientific be one of the UK’s best growth stocks to…

Read more »

piggy bank, searching with binoculars
Investing Articles

Can the rampant Barclays share price beat Lloyds in 2026?

Harvey Jones says the Barclays share price was neck and neck with Lloyds over the last year, and checks out…

Read more »

Investing Articles

Here’s how Rolls-Royce shares could hit £25 in 2026

If Rolls-Royce shares continue their recent performance, then £25 might be on the cards for 2026. Let's take a look…

Read more »

Departure & Arrival sign, representing selling and buying in a portfolio
Investing Articles

Prediction: in 2026 the red-hot Rolls-Royce share price could turn £10,000 into…

Harvey Jones can't believe how rapidlly the Rolls-Royce share price has climbed. Now he looks at the FTSE 100 growth…

Read more »